Should biologics be used as first-line therapy in the treatment of spondyloarthritides (SpA) or are NSAIDs still the preferred option? A pro-and-con discussion explored this question at this year’s DGIM Congress.
This content is machine-translated. Please contact us if you need professional translation services.
Autoren
- Jens Dehn
Publikation
- InFo RHEUMATOLOGIE
Related Topics
You May Also Like
- Suspicion of coronary heart disease
Stress echocardiography, MR heart or computed tomography heart?
- Cardiorenal syndrome
Cross-talk between heart and kidney
- Chronic urticaria
“Treat-to-target” approach is underpinned by new findings
- Dual GIP/GLP-1 RA in type 2 diabetes
Tirzepatide proves multiple benefits
- Pain syndrome
From pathophysiology to therapy – a reminder
- Sunscreen
Increasing risk of skin cancer due to dangerous UV radiation
- Coronary heart disease and type 2 diabetes
Relationship between baseline FFA values and all-cause mortality.
- Visceral Surgery Update - Part 1